One intravenous infusion, and your liver cells start making their own clotting factor.
In a country where more than 30,000 people live under the shadow of unpredictable bleeding, two biotech companies have joined forces to bring a new kind of medicine closer to those who need it most. Belief BioMed and Grand Life Sciences have formed an exclusive partnership to develop and commercialize BBM-H803, a gene therapy that could one day replace the endless cycle of injections hemophilia A patients endure with a single, lasting intervention. The agreement, spanning mainland China and its territories, reflects a broader human aspiration: to move beyond managing suffering and toward something closer to a cure.
- More than 30,000 registered hemophilia A patients in China face daily uncertainty — spontaneous bleeds, joint damage, and a treatment regimen that demands constant vigilance and carries its own risks.
- Current factor VIII replacement therapies offer no permanence, leaving patients tethered to frequent injections and vulnerable to infection, a burden that compounds the disorder's physical toll with psychological strain.
- BBM-H803 proposes a fundamentally different logic: a single intravenous delivery of a viral vector that reprograms liver cells to produce their own clotting factor, potentially ending the cycle of dependency.
- The partnership pairs Belief BioMed's proprietary gene therapy science — already proven with China's first hemophilia B therapy in 2025 — with Grand Life Sciences' vast distribution infrastructure spanning hundreds of thousands of outlets nationwide.
- Regulatory momentum is building, with FDA orphan drug and rare pediatric disease designations secured and China's NMPA having approved an investigational new drug application, though full approval remains ahead.
Two biotech companies announced this week a partnership that could meaningfully change life for tens of thousands of Chinese patients living with hemophilia A — a genetic disorder that leaves the body unable to produce sufficient clotting factor VIII, causing unpredictable bleeding into joints and soft tissue, and in severe cases, permanent disability.
Belief BioMed, a Shanghai-based gene therapy company, has granted Grand Life Sciences exclusive rights to commercialize BBM-H803 across mainland China, Hong Kong, Macau, and Taiwan. The pairing is deliberate: Belief BioMed brings deep research capabilities and proprietary manufacturing techniques; Grand Life Sciences brings a nationwide distribution network and established commercial infrastructure. Together, they are betting that the science is ready to meet the scale of the need.
BBM-H803 is an AAV-based gene therapy that delivers the missing clotting gene directly into liver cells via a single intravenous infusion. Once those cells begin producing their own factor VIII, patients may be protected from bleeding episodes long-term — without the repeated injections that currently define their lives. China's more than 30,000 registered hemophilia A patients largely depend on factor VIII replacement therapy, a regimen that is both burdensome and imperfect.
The therapy has been advancing steadily. An investigator-initiated trial launched in 2022. The FDA granted orphan drug designation that December, followed by China's NMPA approving an investigational new drug application in July 2023, and a rare pediatric disease designation from the FDA in October 2024. Belief BioMed is not without precedent here — in 2025, it launched China's first gene therapy for the related condition hemophilia B, a milestone that appears to have sharpened its ambitions.
BBM-H803 has not yet been approved for marketing anywhere, and late-stage trials remain ahead. But the partnership signals genuine conviction — from companies with the resources to know the difference between promising science and transformative medicine — that this therapy may one day be both.
Two biotech companies announced a partnership this week that could reshape treatment options for tens of thousands of Chinese patients living with hemophilia A, a bleeding disorder that forces them into a cycle of frequent injections and the constant fear of spontaneous hemorrhage.
Belief BioMed, a Shanghai-based gene therapy company, has granted Grand Life Sciences exclusive rights to commercialize BBM-H803 across mainland China, Hong Kong, Macau, and Taiwan. The agreement, signed by Xiao Xiao, Belief BioMed's co-founder and chief science officer, and Zenghui Feng, chairman of Grand Life Sciences, pairs a company with deep research capabilities against one with established distribution networks and market reach. The logic is straightforward: Belief BioMed has the science; Grand Life Sciences has the channels to get it to patients who need it.
Hemophilia A is a genetic disorder rooted in the body's inability to produce sufficient clotting factor VIII. Without it, patients bleed unpredictably—into joints, muscles, soft tissue—sometimes without any obvious trigger. Repeated bleeding into the same joints can cause permanent deformity and disability. In China, the condition affects somewhere between 2.73 and 3.09 people per 100,000, which translates to more than 30,000 registered cases. Most of these patients depend on factor VIII replacement therapy, which requires regular injections and carries its own risks, including exposure to infection. The current treatment landscape leaves them with limited options and inconsistent access to care.
BBM-H803 represents a different approach. It is an AAV-based gene therapy—a viral vector designed to slip past the body's defenses and deliver the missing gene directly into liver cells. Once there, those cells begin producing their own clotting factor VIII, potentially providing long-term protection against bleeding episodes without the burden of repeated injections. The therapy is administered intravenously, a single intervention rather than an ongoing regimen. Belief BioMed developed the drug using proprietary manufacturing techniques, including a serum-free suspension culture process that meets pharmaceutical manufacturing standards.
The timeline matters. An investigator-initiated trial began in 2022. In December of that year, the U.S. FDA granted the therapy orphan drug designation, recognizing its potential to address a rare disease with few treatment alternatives. China's National Medical Products Administration approved an investigational new drug application in July 2023. In October 2024, the FDA awarded it rare pediatric disease designation. These regulatory milestones suggest the therapy is moving through the development pipeline, though it has not yet been approved for marketing anywhere.
Belief BioMed is not new to this space. In 2025, the company launched China's first gene therapy for hemophilia B, a related but distinct bleeding disorder. That success appears to have emboldened the company to pursue hemophilia A, where the unmet need is arguably even larger. Xiao Xiao framed the partnership as a natural extension of that work, combining Belief BioMed's clinical development expertise with Grand Life Sciences' commercialization muscle. Grand Life Sciences, headquartered in Beijing, operates blood product subsidiaries and maintains distribution networks across China's provinces, reaching hundreds of thousands of outlets. The company also has established R&D centers in five major cities and more than 30 product pipelines in various stages of development.
For hemophilia A patients, the promise is tangible: relief from the physical toll of frequent injections and the psychological weight of living under the threat of spontaneous bleeding. For China's gene therapy sector, the partnership signals continued momentum in a field that has begun to mature from laboratory curiosity to clinical reality. The agreement does not guarantee success—BBM-H803 still faces the long road of late-stage clinical trials and regulatory approval—but it does suggest that companies with the resources and expertise believe the science is sound enough to bet on.
Notable Quotes
By combining Belief BioMed's solid clinical development expertise with Grand Life Sciences' robust commercialization capabilities, we are creating a powerful synergy to jointly advance the commercialization of gene therapies for hemophilia A.— Dr. Xiao Xiao, Co-founder and Chief Science Officer of Belief BioMed
Our shared goal is to enable more hemophilia A patients to benefit earlier, relieving them from the physical burden of frequent injections and the fear of bleeding episodes.— Zenghui Feng, Chairman of Grand Life Sciences Group
The Hearth Conversation Another angle on the story
Why does a partnership like this matter? Isn't this just two companies making a business deal?
On the surface, yes. But what's actually happening is that a therapy that might help 30,000 people in China is being handed from a company that invented it to a company that can actually reach those patients. Without that handoff, the science stays locked in a lab.
So Grand Life Sciences is the distribution piece?
Exactly. They have blood product subsidiaries, sales networks in every province, relationships with hospitals and clinics. Belief BioMed has the gene therapy expertise. Neither company alone can do what they're trying to do together.
What's the actual treatment like for a hemophilia A patient right now?
Frequent injections of clotting factor. It works, but it's exhausting—physically and psychologically. You're managing a chronic condition that never goes away. And there's always the fear of a bleed you can't control.
And this gene therapy would change that?
In theory, yes. One intravenous infusion, and your liver cells start making their own clotting factor. Long-term protection without the injection schedule. But it's still investigational. It hasn't been approved yet.
How far along is it?
Far enough that the FDA has recognized it twice—orphan drug designation, then rare pediatric disease designation. China approved it for investigational use in 2023. There's an ongoing trial. But approval is still ahead.
What does this say about China's gene therapy sector?
That it's real. Belief BioMed already launched a hemophilia B gene therapy in 2025. Now they're moving to hemophilia A. These aren't hypothetical treatments anymore. They're in patients.